Our proposal to explore human cytomegalovirus (HCMV) disease pathogenesis in lung transplant recipients has been funded by CIHR! 🎉 I will be hiring 1 MSc and 1 PhD student for Fall 2026. Students can apply through LMP or IMS. Interested? Send your CV & transcript to [email protected].

My lab is looking for a post-doctoral fellow (PDF) to work on an exciting new translational immunology project developing and testing virus-specific T cell therapies for ex vivo organ perfusion and transplantation. Apply here ⤵️ jobs.smartrecruiters.com/UniversityHe...

Today is my 11th year anniversary at @uhnresearch.ca! Very thankful for the amazing colleagues, trainees and friends I've made over the years and excited for the new connections and discoveries on the horizon.

Our first publication addressing RSV vaccination in transplant recipients is now available in Clinical Microbiology and Infection: www.sciencedirect.com/science/arti... We found marginal rates of seroconversion but robust CD4+ T cell responses after a single dose of adjuvanted vaccine.

Our latest work 🚨 a first-in-human study: We show that rituximab delivery via ex vivo lung perfusion is feasible and safe. With some modifications, this could become a new way to eliminate EBV in donor lungs prior to transplantation. journals.lww.com/transplantat...

UHN, Canada’s top hospital, is ranked third in the world for the second year in a row by @newsweek.com! This 2025 ranking solidifies UHN’s Toronto General Hospital as the top publicly-funded hospital in the world. Read the full report here: www.newsweek.com/rankings/wor...

In Press and Open Access! "Using machine learning for personalized prediction of longitudinal coronavirus disease 2019 vaccine responses in transplant recipients" by Azarfar et al. https://buff.ly/43u19aH @victorhferreira.bsky.social #MachineLearning #SolidOrganTransplantation #Vaccination

Can anyone shed light on the new CIHR rankings? Is it safe to assume that all projects that rank in top 10% will be funded? Do we expect that some applications in the 11-25% rank will also be funded?

While immunocompromised individuals had a heterogeneous antibody response to RSV vaccines, those who received the adjuvanted RSVPreF3-AS01 vaccine showed better neutralization. ja.ma/4iVzJzy

Excellent study by my Penn-CEIRR colleagues showing that a single HA substitution in H5 (at same exact residue that changed in the British Columbia case!) enables efficient H5N1 binding to receptors in the human upper airway. www.science.org/doi/10.1126/...

Can machine learning be used to predict SARS-CoV-2 vaccine responses in immunocompromised transplant recipients one year after their first dose of vaccine? Our latest study, accepted at American Journal of Transplantation, explores this question: tinyurl.com/59ehzfmk.

Pleased to share that our project (led by Victoria Hall, Atul Humar, Deepali Kumar, and myself) was one of 35 selected for funding to address the risk of avian influenza in Canada. We will study H5 vaccine responses & safety in immunocompromised transplant recipients. www.canada.ca/en/institute...